1. | jcacrmn | |
2. | teckback | |
3. | hgresser | |
4. | bigwhit244 | |
5. | grummananan |
1. | jcacrmn | |
2. | teckback | |
3. | hgresser | |
4. | bigwhit244 | |
5. | grummananan |
1. | hgresser 02/06/2018 Where Is Synergy Pharmaceuticals Inc Heading From Here? H.C. Wainwright Weighs In - Smarter Analyst |
2. | hgresser 10/30/2018 Synergy Pharmaceuticals (SGYP) Stock: When Enough Is Enough |
3. | bigwhit244 05/15/2018 Synergy Pharmaceuticals (SGYP): Can Trulance Uptake Grow Stronger? Oppenheimer and Cantor Weigh in |
4. | jcacrmn 05/10/2018 Synergy Pharmaceuticals (SGYP) Stock Sinks on Disappointing Earnings Update |
5. | teckback 01/25/2018 Announces FDA approval of TRULANCE (Plecanatide) for the treatment of irritable bowel syndrome with constipa… |
6. | teckback 05/11/2018 Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results and Business Update |
7. | jcacrmn 01/25/2018 Great news today! - Cantor Fitzgerald reiterates Buy rating, $10 PT |
8. | jcacrmn 02/01/2018 Big news out... - H.C. Wainwright & Co. reiterates Buy rating, $7 PT |
9. | teckback 05/07/2018 H.C. Wainwright & Co. sets PT at $7 |
10. | hgresser 01/25/2018 Synergy Pharmaceuticals Inc Enters a Fiercely Competitive IBS-C Market, But |